Johnson and Johnson one-shot COVID-19 vaccine effective and safe

Johnson & Johnson’s one-shot COVID-19 vaccine appeared safe and effective in trials, U.S. Food and Drug Administration (FDA) staff said in documents published on Wednesday, paving the way for its approval for emergency use.

The FDA’s panel of independent experts meets on Friday to decide whether to approve the shot. While it is not bound to follow its experts’ advice, the FDA usually does and has authorized vaccines from Pfizer and Moderna.

J&J said in documents submitted to the FDA that its data suggested its vaccine was effective at preventing asymptomatic infections. It said that in a preliminary analysis of its trial, it found 16 cases of asymptomatic cases in the placebo group versus two in the vaccine group, or an 88% efficacy rate.

J&J’s COVID-19 Vaccine Capability

Vials with a sticker reading, “COVID-19 / Coronavirus vaccine / Injection only” and a medical syringe are seen in front of a displayed Johnson & Johnson logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration

While asymptomatic infection was not the primary goal of the trial, which studied the vaccine’s ability to stop moderate to severe COVID-19, reducing asymptomatic cases implies the shot can also cut transmission of the disease.

J&J’s vaccine was 66% effective in preventing COVID-19 against multiple variants in a global trial involving nearly 44,000 people. The company said last month.

Its effectiveness varied from 72% in the United States to 66% in Latin America and 57% in South Africa, where a new variant has spread. However, the vaccine was 85% effective overall in stopping severe cases of the disease.

The vaccine effectively reduced the risk of COVID-19 and prevented PCR-test confirmed COVID-19 at least 14 days after vaccination, the FDA said in its briefing documents.

Fourteen days after injection, only two vaccine recipients developed COVID-19 severe enough to need medical intervention, compared with 14 in the placebo group. After 28 days, no vaccine recipients developed COVID severe enough to require medical intervention, whereas seven in the placebo group did.

Three vaccine recipients had severe side effects in the trial that were likely related to the vaccine. Still, the FDA said its analysis did not raise any specific safety concerns that would preclude the issuance of an emergency use authorization.

The FDA said the most common solicited adverse reactions were injection site pain at 48.6%, headache at 39%, fatigue at 38.2%, and myalgia at 33.2%. Other side effects included fever in 9% of participants and high fever in 0.2% of those who received the vaccine.

The regulator said one case of pericarditis, a heart disease, may have been caused by the vaccine. It said cases of a rare disorder, Guillain-Barre Syndrome, were unlikely to be related to the shot though data was insufficient to determine whether or not the vaccine had caused these side effects.

J&J had not previously released details of its clinical trial data beyond efficacy rates.

(Reporting by Manas Mishra in Bengaluru; Mike Erman, Caroline Humer, and Rebecca Spalding; Editing by Bernard Orr and David Clarke)

Related Articles

How to Relax With CBD

Best Hiking Gear on Amazon